Pittler MH, Ernst E.
Ginkgo biloba
extract for the treatment of intermittent claudication: a meta-analysis of randomized trials.
Am J Med
. 2000;108:276 - 281.
Peters H, Kieser M, Holscher U. Demonstration of the efficacy of ginkgo biloba special extract EGb 761 on intermittent claudication - a placebo-controlled, double-blind multicenter trial.
Vasa
. 1998;27:106 - 110.
Blume J, Kieser M, Holscher U. Placebo-controlled, double-blind study on the effectiveness of ginkgo biloba special extract EGb 761 in trained patients with intermittent claudication [translated from German].
Vasa.
1996;25:265 - 274.
Schweizer J, Hatmann C. Comparison of two dosages of
Ginkgo biloba
extract EGb 761 in patients with peripheral arterial occlusive disease Fontaine's Stage IIb. A randomized, double-blind, multicentric clinical trial.
Arzneimittelforschung.
1999;49:900 - 904.
Sabba C, Berardi E, Antonica G, et al. Comparison between the effect of L-propionylcarnitine, L-acetylcarnitine and nitroglycerin in chronic peripheral arterial disease: a haemodynamic double blind echo-Doppler study.
Eur Heart J.
1994;15:1348 - 1352.
Brevetti G, Diehm C, Lambert D. European multicenter study on propionyl-L-carnitine in intermittent claudication.
J Am Coll Cardiol
. 1999;34:1618 - 1624.
Brevetti G, Perna S, Sabba C, et al. Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study.
J Am Coll Cardiol
. 1995;26:1411 - 1416.
Bolognesi M, Amodio P, Merkel C, et al. Effect of 8-day therapy with propionyl-L-carnitine on muscular and subcutaneous blood flow of the lower limbs in patients with peripheral arterial disease.
Clin Physiol
. 1995;15:417 - 423.
Brevetti G, Perna S, Sabba C, et al. Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study.
Eur Heart J
. 1992;13:251 - 255.
Greco AV, Mingrone G, Bianchi M, et al. Effect of propionyl-L-carnitine in the treatment of diabetic angiopathy: controlled double blind trial versus placebo.
Drugs Exp Clin Res
. 1992;18:69 - 80.
Brevetti G, Chiariello M, Ferulano G, et al. Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study.
Circulation
. 1988;77:767 - 773.
Deckert J. Propionyl-L-carnitine for intermittent claudication.
J Fam Pract
. 1997;44:533 - 534.
Sabba C, Berardi E, Antonica G, et al. Comparison between the effect of L-propionylcarnitine, L-acetylcarnitine and nitroglycerin in chronic peripheral arterial disease: a haemodynamic double blind echo-Doppler study.
Eur Heart J
. 1994;15:1348 - 1352.
Pepine CJ. The therapeutic potential of carnitine in cardiovascular disorders.
Clin Ther
. 1991;13:2 - 21.
Brevetti G, Attisano T, Perna S, et al. Effect of L-carnitine on the reactive hyperemia in patients affected by peripheral vascular disease: a double-blind, crossover study.
Angiology
. 1989;40:857 - 862.
Hiatt WR, Regensteiner JG, Creager MA, et al. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication.
Am J Med
. 2001;110:616 - 622.
O'Hara J, Jolly PN, Nicol CG. The therapeutic efficacy of inositol nicotinate (Hexopal) in intermittent claudication: a controlled trial.
Br J Clin Pract
. 1988;42:377 - 383.
Kiff RS, Quick CR. Does inositol nicotinate (Hexopal) influence intermittent claudication? A controlled trial.
Br J Clin Pract
. 1988;42:141 - 145.
Head A. Treatment of intermittent claudication with inositol nicotinate.
Practitioner
. 1986;230:49 - 54.
Tyson VCH. Treatment of intermittent claudication.
Practitioner
. 1979;223:121 - 126.
O'Hara J, Jolly PN, Nicol CG. The therapeutic efficacy of inositol nicotinate (Hexopal) in intermittent claudication: a controlled trial.
Br J Clin Pract
. 1988;42:377 - 383.
Castano G, Mas Ferreiro R, Fernandez L, et al. A long-term study of policosanol in the treatment of intermittent claudication.
Angiology
. 2001;52:115 - 125.
Castano G, Mas R, Roca J, et al. A double-blind, placebo-controlled study of the effects of policosanol in patients with intermittent claudication.
Angiology
. 1999;50:123 - 130.
Arruzazabala ML, Valdes S, Mas R, et al. Effect of policosanol successive dose increases on platelet aggregation in healthy volunteers.
Pharmacol Res
. 1996;34:181 - 185.
Arruzazabala ML, Valdes S, Mas R, et al. Comparative study of policosanol, aspirin and the combination therapy policosanol-aspirin on platelet aggregation in healthy volunteers.
Pharmacol Res
. 1997;36:293 - 297.
Maxwell A, Anderson B, Cooke JP. Improvement in walking distance and quality of life in peripheral arterial disease by a nutritional product designed to enhance nitric oxide activity [abstract].
J Am Coll Cardiol
. 1999;33(2 suppl A):277A
Tornwall ME, Virtamo J, Haukka JK, et al. The effect of alpha-tocopherol and beta-carotene supplementation on symptoms and progression of intermittent claudication in a controlled trial.
Atherosclerosis.
1999;147:193 - 197.
Nenci GG, Gresele P, Ferrari G, et al. Treatment of intermittent claudication with mesoglycan--a placebo-controlled, double-blind study.
Thromb Haemost.
2001;86:1181 - 1187.
Maxwell AJ, Anderson BE, Cooke JP. Nutritional therapy for peripheral arterial disease: a double-blind, placebo-controlled, randomized trial of HeartBar.
Vasc Med.
2000;5(1):11-9.
Boger RH, Bode-Boger SM, Thiele W, et al. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease.
J Am Coll Cardiol.
1998;32:1336 - 1344.
Castano G, Mas R, Fernandez L, et al. Effects of policosanol and lovastatin in patients with intermittent claudication: a double-blind comparative pilot study.
Angiology
. 2003;54:25 - 38.
Último revisado Octubre 2003 por EBSCO CAM Medical Review Board
La información aquí suministrada complementa la atención recibida por su médico. De ninguna forma intenta sustituir el consejo de un professional medico. LLAME A SU MEDICO DE INMEDIATO SI PIENSA QUE PODRIA TENER UNA EMERGENCIA. Siempre busque consejo médico antes de comenzar un nuevo tratamiento o si tiene preguntas sobre una condición médica.
Copyright © EBSCO Publishing. All rights reserved.